Th17-Gene Expression Profile in Patients with Chronic Venous Disease and Venous Ulcers: Genetic Modulations and Preliminary Clinical Evidence

Chronic venous disease is a condition globally widespread, resulting in a disabling pathological disorder. The CD4 + Th17+ (Cluster Differentiation 4) lymphocytes represent a regulative factor for innate immunity related to the development of complex diseases. Recently, these mechanisms have been associated with vascular disease. The aim of this work is to validate whether the Th17 response correlates with the development of CVI (Chronic venous insufficiency)and CVLUs (chronic venous limbs ulcers) and whether Th17 markers can be used, both as intrinsic risk factors and diagnostic markers, for disease development. PBL derived from peripheral blood samples of patients and controls were subjected to gene expression analysis for IL23R, IL17, SGK1, TGFβ, RORγ, FOXO1, and RANBP1 by qRT-PCR and immunoblot. A post hoc correlation, the diagnostic performance of the target genes, and multivariable analyses were properly conducted. The main expression markers of the CD4 + Th17+ switch were strongly activated in chronic venous insufficiency and in advanced ulceration. The correlation analysis demonstrated the inter-dependence on Th17’s signature modulation. ROC (Receiver Operating Characteristic) analysis defined, for the examined genes, a clinical value as the potential diagnostic markers. Multi-logistic regression studies showed that Th17 markers behave as empirical risk factors for CVD (chronic venous disease) development. Taken together, the present data provide a new hypothesis for the TH17-dependent pathogenesis of CVD, favoring the possibility for the development of new diagnostic, preventive, and therapeutic approaches.

[1]  Zhihui Zhang,et al.  Parthenolide Suppresses T Helper 17 and Alleviates Experimental Autoimmune Encephalomyelitis , 2022, Frontiers in Immunology.

[2]  J. Routy,et al.  Th17 CD4+ T-Cell as a Preferential Target for HIV Reservoirs , 2022, Frontiers in Immunology.

[3]  F. F. de Melo,et al.  Relationship between Th17 immune response and cancer , 2021, World journal of clinical oncology.

[4]  R. Flisiak,et al.  The Role of Th17 Response in COVID-19 , 2021, Cells.

[5]  Maarten van Smeden,et al.  Risk prediction models for discrete ordinal outcomes: Calibration and the impact of the proportional odds assumption , 2021, Statistics in medicine.

[6]  M. Gennarelli,et al.  The Emerging Role of SGK1 (Serum- and Glucocorticoid-Regulated Kinase 1) in Major Depressive Disorder: Hypothesis and Mechanisms , 2020, Frontiers in Genetics.

[7]  W. Marston,et al.  CEAP classification system and reporting standard, revision 2020. , 2020, Journal of vascular surgery. Venous and lymphatic disorders.

[8]  R. Serra,et al.  Genetic biomarkers in chronic venous disease. , 2020, Biomarkers in medicine.

[9]  F. Trapasso,et al.  Review about the multi-target profile of resveratrol and its implication in the SGK1 inhibition. , 2019, European journal of medicinal chemistry.

[10]  P. Matarrese,et al.  The small molecule SI113 hinders epithelial‐to‐mesenchymal transition and subverts cytoskeletal organization in human cancer cells , 2019, Journal of cellular physiology.

[11]  C. Bucca,et al.  Th1- and Th17-Related Cytokines in Venous and Arterial Blood of Sclerodermic Patients with and without Digital Ulcers , 2019, BioMed research international.

[12]  F. Musumeci,et al.  In Preclinical Model of Ovarian Cancer, the SGK1 Inhibitor SI113 Counteracts the Development of Paclitaxel Resistance and Restores Drug Sensitivity , 2019, Translational oncology.

[13]  J. Routy,et al.  New Th17-specific therapeutic strategies for HIV remission , 2019, Current opinion in HIV and AIDS.

[14]  Xiao-qiang Yu,et al.  Inflammasome activation and Th17 responses , 2019, Molecular immunology.

[15]  K. Brown,et al.  Characterization of the Src-regulated kinome identifies SGK1 as a key mediator of Src-induced transformation , 2019, Nature Communications.

[16]  V. Ventura,et al.  Deregulation of SGK1 in Ulcerative Colitis: A Paradoxical Relationship Between Immune Cells and Colonic Epithelial Cells. , 2018, Inflammatory bowel diseases.

[17]  A. Madi,et al.  SGK1 Governs the Reciprocal Development of Th17 and Regulatory T Cells , 2018, Cell reports.

[18]  L. Insabato,et al.  The SGK1 inhibitor SI113 induces autophagy, apoptosis, and endoplasmic reticulum stress in endometrial cancer cells , 2017, Journal of cellular physiology.

[19]  E. Gallo,et al.  The small molecule SI113 synergizes with mitotic spindle poisons in arresting the growth of human glioblastoma multiforme , 2017, Oncotarget.

[20]  F. Calabria,et al.  The SGK1 Kinase Inhibitor SI113 Sensitizes Theranostic Effects of the 64CuCl2 in Human Glioblastoma Multiforme Cells , 2017, Cellular Physiology and Biochemistry.

[21]  S. Schenone,et al.  SGK1 affects RAN/RANBP1/RANGAP1 via SP1 to play a critical role in pre-miRNA nuclear export: a new route of epigenomic regulation , 2017, Scientific Reports.

[22]  I. Monteleone,et al.  Sodium chloride–enriched Diet Enhanced Inflammatory Cytokine Production and Exacerbated Experimental Colitis in Mice , 2017, Journal of Crohn's & colitis.

[23]  R. Serra,et al.  Functional chronic venous disease: A systematic review , 2017, Phlebology.

[24]  S. Schenone,et al.  SGK1, the New Player in the Game of Resistance: Chemo-Radio Molecular Target and Strategy for Inhibition , 2016, Cellular Physiology and Biochemistry.

[25]  F. Musumeci,et al.  SI113, a SGK1 inhibitor, potentiates the effects of radiotherapy, modulates the response to oxidative stress and induces cytotoxic autophagy in human glioblastoma multiforme cells , 2016, Oncotarget.

[26]  M. Kleinewietfeld,et al.  Sodium chloride, SGK1, and Th17 activation , 2015, Pflügers Archiv - European Journal of Physiology.

[27]  R. McKinley,et al.  The impact of chronic venous leg ulcers: a systematic review. , 2014, Journal of Wound Care.

[28]  G. Cuda,et al.  Sgk1 enhances RANBP1 transcript levels and decreases taxol sensitivity in RKO colon carcinoma cells , 2013, Oncogene.

[29]  N. Yosef,et al.  Sodium chloride drives autoimmune disease by the induction of pathogenic TH17 cells , 2013, Nature.

[30]  J. Raffetto Inflammation in chronic venous ulcers , 2013, Phlebology.

[31]  A. Regev,et al.  Induction of pathogenic Th17 cells by inducible salt sensing kinase SGK1 , 2013, Nature.

[32]  M. Jordan,et al.  Diversity of IL-17-producing T lymphocytes , 2012, Cellular and Molecular Life Sciences.

[33]  R. Serra,et al.  A genetic study of chronic venous insufficiency. , 2012, Annals of vascular surgery.

[34]  I. Monteleone,et al.  Th17-related cytokines in inflammatory bowel diseases: friends or foes? , 2012, Current molecular medicine.

[35]  I. Monteleone,et al.  Th17-related cytokines: new players in the control of chronic intestinal inflammation , 2011, BMC medicine.

[36]  K. Ley,et al.  Interleukin 17 in vascular inflammation. , 2010, Cytokine & growth factor reviews.

[37]  T. Grzela,et al.  Genetic risk factors of chronic venous leg ulceration: Can molecular screening aid in the prevention of chronic venous insufficiency complications? , 2010, Molecular medicine reports.

[38]  F. Caprioli,et al.  Th17 immune response in IBD: A new pathogenic mechanism. , 2008, Journal of Crohn's & colitis.

[39]  T. Sándor Pathomechanism of chronic venous insufficiency and leg ulcer. , 2004, Acta physiologica Hungarica.

[40]  T. Moseley,et al.  Interleukin-17 family and IL-17 receptors. , 2003, Cytokine & growth factor reviews.

[41]  P. Smith Update on chronic-venous-insufficiency-induced inflammatory processes. , 2001, Angiology.

[42]  C. Haft,et al.  Activation of Serum- and Glucocorticoid-induced Protein Kinase (Sgk) by Cyclic AMP and Insulin* , 2001, The Journal of Biological Chemistry.